Mark Mahaney, Evercore ISI head of internet research, joins 'Closing Bell' to discuss the markets, Meta's historic winning ...

Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) from In-Line to Outperform. Analyst Price Forecast Suggests 90.46% Upside As ...

Confluent (NASDAQ:CFLT – Get Free Report) had its target price upped by Evercore ISI from $32.00 to $40.00 in a report ...

Wall Street investment bank Evercore ISI (EVR) is pounding the table on Nvidia (NVDA) stock ahead of the chipmaker’s upcoming ...

Evercore ISI analyst Michael Lonegan lowered the firm’s price target on PG&E to $15 from $20 and keeps an In Line rating on the shares. The ...

The Carlyle Group (NASDAQ:CG – Get Free Report) had its price target hoisted by analysts at Evercore ISI from $51.00 to $52.00 in a report issued on Wednesday,Benzinga reports. The firm presently has ...

Rich Ross, head of technical analysis at Evercore ISI, said that a breakout to an all-time high in the S&P 500 ( SP500 ), ( ...

Evercore ISI analyst Liisa Bayko raised the price target for CRISPR Therapeutics from $60.00 to $99.00. Bayko's optimism is driven by upcoming catalysts that could mark a new chapter for the company.

Fears that DeepSeek may be moving AI workloads from Nvidia's GPUs to Application-Specific Integrated Circuits combined with possible delays in the Blackwell chip release have caused lags in Nvidia ...

Nvidia shares gained Monday, leading other chip stocks higher in a boost to the tech sector as the major U.S. indexes looked ...